Mig-6 controls EGFR trafficking and suppresses gliomagenesis.

TitleMig-6 controls EGFR trafficking and suppresses gliomagenesis.
Publication TypeJournal Article
Year of Publication2010
AuthorsYing H, Zheng H, Scott K, Wiedemeyer R, Yan H, Lim C, Huang J, Dhakal S, Ivanova E, Xiao Y, Zhang H, Hu J, Stommel JM, Lee MA, Chen A-J, Paik J-H, Segatto O, Brennan C, Elferink LA, Y Wang A, Chin L, DePinho RA
JournalProc Natl Acad Sci U S A
Volume107
Issue15
Pagination6912-7
Date Published2010 Apr 13
ISSN1091-6490
KeywordsAdaptor Proteins, Signal Transducing, Animals, Brain Neoplasms, Cell Adhesion, Cell Line, Tumor, Cell Proliferation, ErbB Receptors, Gene Expression Regulation, Neoplastic, Glioma, Humans, Intracellular Signaling Peptides and Proteins, Lysosomes, Mice, Neoplasm Invasiveness, Tumor Suppressor Proteins, Two-Hybrid System Techniques
Abstract

Glioblastoma multiforme (GBM) is the most common and lethal primary brain cancer that is driven by aberrant signaling of growth factor receptors, particularly the epidermal growth factor receptor (EGFR). EGFR signaling is tightly regulated by receptor endocytosis and lysosome-mediated degradation, although the molecular mechanisms governing such regulation, particularly in the context of cancer, remain poorly delineated. Here, high-resolution genomic profiles of GBM identified a highly recurrent focal 1p36 deletion encompassing the putative tumor suppressor gene, Mig-6. We show that Mig-6 quells the malignant potential of GBM cells and dampens EGFR signaling by driving EGFR into late endosomes and lysosome-mediated degradation upon ligand stimulation. Mechanistically, this effect is mediated by the binding of Mig-6 to a SNARE protein STX8, a protein known to be required for late endosome trafficking. Thus, Mig-6 functions to ensure recruitment of internalized receptor to late endosomes and subsequently the lysosomal degradation compartment through its ability to specifically link EGFR and STX8 during ligand-stimulated EGFR trafficking. In GBM, the highly frequent loss of Mig-6 would therefore serve to sustain aberrant EGFR-mediated oncogenic signaling. Together, these data uncover a unique tumor suppression mechanism involving the regulation of receptor trafficking.

DOI10.1073/pnas.0914930107
Alternate JournalProc Natl Acad Sci U S A
PubMed ID20351267
Grant ListCA119075 / CA / NCI NIH HHS / United States
R01CA99041 / CA / NCI NIH HHS / United States
5P01CA95616 / CA / NCI NIH HHS / United States
Related Faculty: 
Hongwu Zheng, Ph.D. Ji-Hye Paik, Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700